Principal Financial Group
BBIO icon

Principal Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Principal Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.3M Sell
1,024,423
-305,992
-23% -$21.4M 0.04% 384
2026
Q1 		$98.8M Buy
1,330,415
+16,112
+1% +$1.17M 0.05% 285
2025
Q4 		$101M Buy
1,314,303
+46,891
+4% +$3.08M 0.05% 274
2025
Q3 		$65.8M Buy
1,267,412
+236,885
+23% +$11.6M 0.03% 380
2025
Q2 		$44.5M Sell
1,030,527
-117,765
-10% -$4.28M 0.02% 496
2025
Q1 		$39.7M Buy
1,148,292
+98,153
+9% +$3.31M 0.02% 513
2024
Q4 		$28.8M Sell
1,050,139
-94,984
-8% -$2.45M 0.02% 665
2024
Q3 		$29.2M Buy
1,145,123
+19,978
+2% +$524K 0.02% 652
2024
Q2 		$28.5M Buy
1,125,145
+51,958
+5% +$1.42M 0.02% 671
2024
Q1 		$33.2M Buy
1,073,187
+129,703
+14% +$4.41M 0.02% 633
2023
Q4 		$38.1M Buy
943,484
+197,818
+27% +$5.94M 0.02% 538
2023
Q3 		$19.7M Buy
745,666
+705,249
+1,745% +$20M 0.01% 813
2023
Q2 		$695K Buy
40,417
+6,946
+21% +$105K ﹤0.01% 1893
2023
Q1 		$555K Buy
33,471
+474
+1% +$5.53K ﹤0.01% 1949
2022
Q4 		$251K Buy
32,997
+2,378
+8% +$22.8K ﹤0.01% 2144
2022
Q3 		$305K Buy
30,619
+1,907
+7% +$19.8K ﹤0.01% 2075
2022
Q2 		$260K Sell
28,712
-4,371
-13% -$36.6K ﹤0.01% 2224
2022
Q1 		$336K Sell
33,083
-275
-0.8% -$2.82K ﹤0.01% 2209
2021
Q4 		$556K Sell
33,358
-14,816
-31% -$627K ﹤0.01% 2103
2021
Q3 		$2.26M Sell
48,174
-2,294
-5% -$123K ﹤0.01% 1846
2021
Q2 		$3.08M Buy
50,468
+2,922
+6% +$167K ﹤0.01% 1822
2021
Q1 		$2.93M Buy
47,546
+3,859
+9% +$252K ﹤0.01% 1786
2020
Q4 		$3.11M Buy
43,687
+6,879
+19% +$332K ﹤0.01% 1697
2020
Q3 		$1.38M Sell
36,808
-1,956
-5% -$61.5K ﹤0.01% 1808
2020
Q2 		$1.26M Buy
38,764
+29,660
+326% +$903K ﹤0.01% 1782
2020
Q1 		$264K Buy
+9,104
New +$282K ﹤0.01% 1994

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Principal Financial Group's BBIO Position: Q2 2026 in Review

Principal Financial Group reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $21.4M and leaving 1,024,423 shares worth $76.3M. The position accounts for 0.04% of the portfolio, ranked #384.

Principal Financial Group first reported a position in BBIO in Q1 2020 and has held it in 26 quarters since. The position peaked at $101M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Principal Financial Group held 1,024,423 shares of BridgeBio Pharma worth $76.3M as of Q2 2026.
  • Principal Financial Group sold 305,992 BridgeBio Pharma shares in Q2 2026, an estimated $21.4M.
  • BridgeBio Pharma made up 0.04% of Principal Financial Group's portfolio in Q2 2026, its #384 holding.
  • Principal Financial Group first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 26 quarters since.
  • Principal Financial Group's BridgeBio Pharma position peaked at $101M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.